|
注册号: Registration number: |
ChiCTR2000029629 |
|
最近更新日期: Date of Last Refreshed on: |
2020-02-08 04:25:15 |
|
注册时间: Date of Registration: |
2020-02-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
類固醇局部注射治療急性前距腓韌帶部分斷裂 |
|
Public title: |
Steroid Local Injection for Acute Anterior Talofibular Ligament Partial Tear |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
類固醇局部注射治療急性前距腓韌帶部分斷裂 |
|
Scientific title: |
Steroid Local Injection for Acute Anterior Talofibular Ligament Partial Tear |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
柳宗廷 |
研究负责人: |
柳宗廷 |
|
Applicant: |
Zongting Liu |
Study leader: |
Zongting Liu |
|
申请注册联系人电话: Applicant telephone: |
+886 935137476 |
研究负责人电话:
Study leader's |
+886 935137476 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
timo9001099@gmail.com |
研究负责人电子邮件: Study leader's E-mail: |
timo9001099@gmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中國臺灣臺北市士林區忠誠路二段22號6樓 |
研究负责人通讯地址: |
中國臺灣臺北市士林區忠誠路二段22號6樓 |
|
Applicant address: |
6th Floor, 22 Second Section, Zhongcheng Road, Shilin District, Taipei City, Taiwan, China |
Study leader's address: |
6th Floor, 22 second section of Zhongcheng Road, Shilin District, Taipei City, Taiwan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
台北馬偕醫院骨科部 |
||
|
Applicant's institution: |
Mackay Memorial Hospital of Taipei |
||
|
研究负责人所在单位: |
台北馬偕醫院骨科部 |
||
|
Affiliation of the Leader: |
Mackay Memorial Hospital of Taipei |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
台北馬偕醫院 |
||||||||||||||||||||||
|
Primary sponsor: |
Mackay Memorial Hospital of Taipei |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中國臺灣臺北市中山區中山北路二段92號 |
||||||||||||||||||||||
|
Primary sponsor's address: |
6th Floor, 22 second section of Zhongcheng Road, Shilin District, Taipei City, Taiwan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
無特殊經費 |
||||||||||||||||||||||
|
Source(s) of funding: |
No funding |
||||||||||||||||||||||
|
研究疾病: |
前距腓韌帶斷裂 |
||||||||||||||||||||||
|
Target disease: |
Anterior talofibular ligament partial tear |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
此研究之目的為,針對踝部急性前距腓韌帶部分斷裂的病人,以接受類固醇局部注射的病人和對照組比較,觀察其效果和是否有副作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
The aim of this study is to compare the effect and complications between patients receiving steroid local injection and control group for acute ankle ATFL partial tear. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.復發性韌帶傷害 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Recurrent sprain injury; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-02-14 00:00:00至 To 2021-05-14 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-02-14 00:00:00 至 To 2021-02-14 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
區組隨機 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Block randomization |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
論文發表後於本網站公開原始數據 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
We will share our raw data after the paper is published. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
ResMan |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |